Data companies band together to form RWE Alliance
Can an industry coalition help craft policy to support the use of Real-World Evidence? Five prominent real-world data and analytics companies are betting on it, launching the RWE Alliance.
Expanding health equity through Covid-driven state Medicaid legislation
Covid has pushed state health agencies to use Medicaid in ways that would never have been imagined before. With one in five Americans saying they are unable to afford healthcare, how are state governments using this historic moment to expand equitable access to care?
presented by
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Using data for anti-racist medical research: An interview with COTA’s chief legal officer
Nadine Peters, chief legal officer of COTA, shares her journey to leadership in health data privacy law and policy recommendations for the Biden Administration on achieving health equity through data use and education.
The “biggest thorn in President Trump’s side” is now HHS Secretary. What’s next?
California Attorney General Xavier Becerra may have won a narrow confirmation to be the Department of Health and Human Services Secretary, but if his past is any indication, his agenda will be bold when it comes to reining in pharma companies, boosting the Affordable Care Act and scrutinizing hospital consolidation.
Avoid legal pitfalls in developing innovative physician-hospital payment structures
While Covid-19 requires physicians and hospitals to be more efficient than ever, a number of legal structures must be considered before providers consolidate their resources. To optimize patient care and ensure rapid payment for services, avoid running afoul of these sometimes counterintuitive regulatory schemes.
How Covid-19 is changing rare diseases research
While Covid has made many aspects of living with a rare disease more difficult, it has inspired policies and techniques that could help rare disease research progress more smoothly both during and after the pandemic.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality
The U.S. Supreme Court heard oral arguments Monday on the constitutionality of the Patent Trial and Appeal Board, an essential piece of the United States patent litigation puzzle and favored tool of generic and biosimilar patent challengers since its formation in 2012.
Promoting public health through the law: A Q&A with NY state counsel Deborah Beth Medows
In a wide-ranging interview, a senior attorney at the state Health Department discusses the national pandemic response, the need to work across the aisle, and lessons learned during a clerkship in Israel.
Lawyers address what we can do and what we must do in vaccine rollout
Hospital counsel, state advisors, congregate care advocates and university leaders believe that public health ethics must drive the next steps in vaccine distribution and not the constraints of the law.
How Tempus’ corporate counsel views healthcare innovation: A Q&A with Maggie Huston
In a wide-ranging interview, Maggie Huston, associate general counsel for precision medicine company Tempus, discusses how to balance innovation with safety as the FDA grapples with AI/ML and new, more complex technology, as well how her company quickly reacted to Covid-19.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
A Q&A with Availity’s senior counsel on data-sharing and the impact of Covid-19
Meet Erich Drotleff, corporate counsel for health IT giant Availity, as he shares his thoughts on the role of data-sharing in public health, the impact of Covid-19 and his passion for bonsai gardening.
Drug price hikes without new evidence upped spending by $1.2B, ICER says
In its report released last Tuesday, a nonprofit drug pricing research group claims that seven drugs have prices that do not align with any newly discovered increase in clinical benefit, leading to over $1.2 billion in excess drug spending in 2019, alone.
Can we warp-speed antibiotic development?
Advocates, industry leaders and legislators have come to a consensus about the scope and urgency of the crisis related to inadequate development of antibiotics. They are calling for legislative fixes to protect public health.
4 takeaways from FDA’s emergency vaccine reviews
What lessons can future Covid vaccine candidates take from the FDA’s response to Pfizer and Moderna’s study data?